RTW Biotech Opportunities Ltd (RTW) Fair Value & Analysis
Financial Services · GB · Market cap $767M
Fair value as of: Jul 15, 2026
From 20 valuation models · updated today
Fair value updated Jul 15, 2026 — revised from $9.27 to $0.0299 (−99.7%) since Jun 11, 2026. Share price +9.0% over the past month.
Price vs Fair Value (12 months)
12‑month range $0.0127 – $0.0247 · fair‑value band $0.0270 – $0.0328 · the $0.0241 price screens below the $0.0299 fair value. As of Jul 15, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
RTW Biotech Opportunities Ltd (RTW) currently trades at $0.0241, while our model-based Fair Value estimate is $0.0299 — implying the stock looks roughly 24.1% undervalued today. We read business quality at 65/100 (solid quality), in the Financial Services sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.
Trailing-twelve-month revenue stands at $34.6M. Revenue declined 10.0% year over year. It earns a return on equity of 32.7%. The balance sheet holds a net cash position of $6.0M. Fundamentals as of Jul 15, 2026
Our scenario range runs from $0.0270 (bear case) to $0.0328 (bull case); at $0.0241, the current price sits below that range. For context, the median of 10 Financial Services peers we cover trades at 53% fair-value upside — at 24%, RTW screens richer than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 15, 2026. TTM = trailing twelve months.
About the company
RTW Biotech Opportunities Ltd is a venture capital fund. The fund specializes in directly investing and early-stage. The fund specializes in identifying transformative assets with high growth potential across the life sciences, biopharmaceutical and medical technology sectors. The fund invests in companies developing next-generation therapies and technologies that can significantly improve patients' lives.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
RTW Biotech Opportunities Ltd reported revenue of $258M in FY2025 versus −$60.9M in FY2021. Reported net income was $245M in FY2025.
Is RTW fairly valued? → Check now
Similar stocks
10 more Asset Management stocks, each showing price versus our Fair Value estimate (as of Jul 15, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Fondul Proprietatea SA FP | $4.20 | $6.41 | +53% |
| The Schiehallion Fund Limited MNTN | $2.27 | $4.54 | +100% |
| BlackRock, Inc BLK | $1,052 | $465.03 | -56% |
| BH Macro Limited BHMU | $4.42 | $8.84 | +100% |
| Blackstone Inc BX | $123.26 | $52.88 | -57% |
| Investor AB INVEB | kr 388.65 | kr 1,430 | +268% |
| BioPharma Credit PLC BPCR | $0.9600 | $1.47 | +53% |
| Brookfield Corporation BN | $43.94 | $9.95 | -77% |
| KKR & Co KKR | C$21.40 | C$5.61 | -74% |
| Brookfield Asset Management Ltd BAM | C$63.81 | C$41.56 | -35% |
Explore undervalued stocks
More undervalued Financial Services stocks →
Frequently asked questions
Is RTW Biotech Opportunities Ltd (RTW) undervalued?
What is the fair value of RTW?
What is the quality score of RTW?
What is the revenue of RTW Biotech Opportunities Ltd (RTW)?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Unlock the full RTW Biotech Opportunities Ltd analysis — and try Pro free
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.